Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $145 from $101 and keeps an Overweight rating on the shares after the company provided its 2026 corporate outlook highlighting new market research and clinical progress ahead of next week’s investment conference in San Francisco. As the firm has continued to interrogate the market opportunity for obefazimod in UC, it has found that experts are increasingly encouraged by both the magnitude of effect and tolerability profile demonstrated in the induction portion of the Phase 3 program, the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax price target raised to $150 from $120 at BTIG
- Abivax SA: Strengthened Outlook for Obefazimod in IBD Drives Higher Target Price and Buy Rating
- – Abivax SA American Depositary Shares call volume above normal and directionally bullish
- Abivax rumored to attract interest from Eli Lilly, La Tribune says
- 5 Stocks That Moved the Most in 2025 – What Lies Ahead